STOPNASH Meeting

停止会议

• 批准号: 8986466
• 负责人: MIRIAM B. VOS
• 金额: $ 2万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8986466
• 关键词: Address; Adipocytes; Adult; Affect; American; Area; Attention; Cardiology; Cardiovascular Diseases; Child; Childhood; Clinical; Collaborations; Communities; Consensus; Diagnosis; Disease; District of Columbia; Endocrinologist; Endocrinology; Environment; Epidemic; Family; Fibrosis; Functional disorder; Gastroenterology; Health; Hepatocyte; Hepatology; Hispanics; Incidence; Inflammation; Insulin Resistance; Knowledge; Lead; Lipids; Liver; Liver diseases; Metabolic; Metabolism; Mission; Names; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Onset of illness; Outcome; Participant; Pathway interactions; Patients; Pattern; Population; Prevalence; Prevention; Public Health; Research; Research Personnel; Science; Scientist; Societies; Staging; Time; Training; United States; Washington; Woman; Work; chronic liver disease; design; diabetes risk; disorder prevention; experience; high risk; improved; interest; meetings; non-alcoholic fatty liver; nonalcoholic steatohepatitis; nutrition; programs; public health relevance; symposium

 DESCRIPTION (provided by applicant): Nonalcoholic fatty liver disease is a chronic liver disease that affects an estimated 10% of the US population including 7 million children. The latest studies on prevalence suggest that the incidence of NAFLD is still rising despite the slowing of the obesity epidemic. Children and adults with NAFLD are at high risk of progressing to end stage liver disease over time and the pathophysiology of NAFLD appears to dramatically increase the risk of diabetes and cardiovascular disease. Because of this and the whole body metabolic dysregulation associated with NAFLD, the research on NAFLD is progressing in many different areas including by pediatric hepatologists, endocrinologists, cardiology, metabolism experts, nutrition scientists, experts in insulin resistance, hepatocyte functions, and adipocyte effects to name just a few. The global aims of this symposium is to bring together experts from diverse fields to move NAFLD research forward, to develop consensus regarding priorities in NAFLD research and to encourage young investigators and investigators from diverse backgrounds to study NAFLD. In order to accomplish these important aims, the "STOPNASH: Symposium on The Origins and Pathways of NASH: Is it Preventable?" one day symposium will be held on October 7th, 2015 at the Washington Hilton, Washington DC in conjunction with the annual meeting of the North American Society of Pediatric Hepatology, Gastroenterology and Nutrition. The overarching theme of this research conference is "what causes the initiation of NASH?" There will be five modules including 1) Clinical patterns informing pathophysiology 2) Systemic metabolic dysregulation associated with NASH 3) Initiation mechanisms of inflammation and fibrosis 4) Research informing prevention and 5) Future research priorities. There will be breakout sessions to promote discussion amongst the researchers and to generate consensus on the most important gaps in research knowledge. Of the 20 experts invited to speak, 8 are women, 2 are Hispanic, and 4 are young investigators. Moderators include 5 young investigators, 3 Hispanic investigators and 50% women. Trainees and young investigators attending will be encouraged to participate in the break-out sessions to discuss research gaps and opportunities. The symposium focuses on a research area that has not been addressed previously in a conference of this type and will provide an excellent training environment for junior investigators interested in pursuing research in NAFLD. We anticipate 150 or more attendees to participate in this unique symposium designed to catalyze the field of NAFLD research, particularly in the area of the onset of the disease. This is expected to lead to synergistic collaborations advancing knowledge to improve outcomes for patients diagnosed with NAFLD in childhood and eventually to promote effective prevention of the disease.

 描述（由申请人提供）： 非酒精性脂肪肝是一种慢性肝病，影响着大约 10% 的美国人口，其中包括 700 万儿童。最新的患病率研究表明，尽管儿童和成人的肥胖流行速度有所放缓，但 NAFLD 的发病率仍在上升。随着时间的推移，NAFLD 进展为终末期肝病的风险很高，而且 NAFLD 的病理生理学似乎会显着增加患糖尿病和心血管疾病的风险，因此该研究表明，NAFLD 与全身代谢失调有关。 NAFLD 的研究正在许多不同领域取得进展，其中包括儿科肝病学家、内分泌学家、心脏病学、代谢专家、营养学家、胰岛素抵抗、肝细胞功能和脂肪细胞影响等领域的专家。本次研讨会的全球目标是汇聚一堂。来自不同领域的专家推动 NAFLD 研究向前发展，就 NAFLD 研究的优先事项达成共识，并鼓励来自不同背景的年轻研究者和研究人员研究 NAFLD。为了实现这些重要目标，“STOPNASH： NASH 的起源和途径研讨会：它可以预防吗？”为期一天的研讨会将于 2015 年 10 月 7 日在华盛顿特区华盛顿希尔顿酒店与北美儿科肝病学、胃肠病学和营养学会年会同时举行本次研究会议的首要主题是“NASH 发生的原因是什么？”将分为五个模块，包括 1) 病理生理学的临床模式 2) 全身代谢与 NASH 相关的失调 3) 炎症和纤维化的引发机制 4) 为预防提供信息的研究 5) 未来的研究重点 将举行分组会议，以促进研究人员之间的讨论，并就研究知识中最重要的差距达成共识。受邀发言的 20 名专家中，8 名是女性，2 名是西班牙裔，4 名是年轻调查员。主持人包括 5 名年轻调查员、3 名西班牙裔调查员以及鼓励 50% 的女性参加。讨论研究差距和机会的分组会议重点讨论以前此类会议中未讨论过的研究领域，并将为初级研究人员提供良好的培训环境。 我们预计将有 150 名或更多与会者参加这一独特的研讨会，该研讨会旨在促进 NAFLD 研究领域，特别是在该疾病的发病领域。知识来改善儿童时期诊断为 NAFLD 的患者的治疗结果，并最终促进该疾病的有效预防。

项目成果

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

开发儿童非酒精性脂肪肝药物时需要考虑的因素。

• DOI: 10.1053/j.gastro.2019.08.048
• 发表时间: 2019-12
• 期刊: Gastroenterology
• 影响因子: 29.4
• 作者: Vos MB;Dimick-Santos L;Mehta R;Omokaro SO;Taminiau J;Schabel E;Kleiner DE;Szitanyi P;Socha P;Schwimmer JB;Noviello S;Silberg DG;Torstenson R;Miller V;Lavine JE;Liver Forum Pediatric Working Group
• 通讯作者: Liver Forum Pediatric Working Group